skip to Main Content
The Wait Continues: DEA Has Yet To Announce Rescheduling Plan For Marijuana

Talk of rescheduling marijuana has kept the cannabis industry and social media ablaze in 2016—the year when theDrug Enforcement Administration will supposedly announce whether it will reclassify marijuana from a Schedule I to a Schedule II drug.

Recent rumors had a decision coming down as early as July 1 — but it looks as though we may have to wait a little longer.

In a letter released in April, the DEA had told lawmakers that it was actively reviewing information to determine whether to reschedule marijuana; the agency estimated an announcement on that decision would come “in the first half of 2016.” But despite the DEA’s self-imposed deadline, the first half of 2016 ended with no announcement. [Read more at Denver Westward]

This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

Guns or marijuana, but not both

While marijuana became legal for adults to purchase in Montana on New Year’s Day, a key federal agency has confirmed a fact underreported in coverage of the state’s new marijuana program: It remains illegal under federal law for individuals to simultaneously possess marijuana or marijuana products and firearms, and penalties for violating that law are…

As Oklahoma’s medical marijuana industry booms, regulators struggle to keep up

Row by row, Oklahoma Bureau of Narcotics and Dangerous Drugs agents and Garvin County deputies cut down 2,500 marijuana plants and loaded them in a dump truck for destruction during an April 2021 raid near Pauls Valley. The grow operation had a Oklahoma Medical Marijuana Authority license, but had not obtained an additional permit from…

European Cannabis Round-Up; GW Pharma’s Cannabis Pipeline, Irish CBD In Court, UK Medical Cannabis Price Row, Italian Referendum, Poland And Malta

GW Pharmaceuticals has released further details of its cannabis development pipeline. With Epidiolex approved in the US last year it is also expecting approval for Sativex where two phase 3 trials are ongoing. Work is also underway on the use of Sativex in spinal cord injury, post-traumatic stress disorder and other forms of spasticity. Further…

ICYMI: Adding Marijuana to a NIST Handbook

by Hilary Bricken, Principle at Harris Bricken Not many people get excited about revisions and updates to the very dry National Institute of Standards and Technology  (“NIST”) handbooks. For example, the NIST 44 Handbook contains the “Specifications, Tolerances, and Other Technical Requirements for Weighing and Measuring Devices.” The handbooks are adopted every year at the…

More Categories

Back To Top
×Close search